These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38990554)

  • 1. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.
    Oberstein PE; Dias Costa A; Kawaler EA; Cardot-Ruffino V; Rahma OE; Beri N; Singh H; Abrams TA; Biller LH; Cleary JM; Enzinger P; Huffman BM; McCleary NJ; Perez KJ; Rubinson DA; Schlechter BL; Surana R; Yurgelun MB; Wang SJ; Remland J; Brais LK; Bollenrucher N; Chang E; Ali LR; Lenehan PJ; Dolgalev I; Werba G; Lima C; Keheler CE; Sullivan KM; Dougan M; Hajdu C; Dajee M; Pelletier MR; Nazeer S; Squires M; Bar-Sagi D; Wolpin BM; Nowak JA; Simeone DM; Dougan SK
    Cancer Immunol Res; 2024 Sep; 12(9):1221-1235. PubMed ID: 38990554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer.
    Koido S; Taguchi J; Shimabuku M; Kan S; Bito T; Misawa T; Ito Z; Uchiyama K; Saruta M; Tsukinaga S; Suka M; Yanagisawa H; Sato N; Ohkusa T; Shimodaira S; Sugiyama H
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39384197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
    Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
    Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
    Overman M; Javle M; Davis RE; Vats P; Kumar-Sinha C; Xiao L; Mettu NB; Parra ER; Benson AB; Lopez CD; Munugalavadla V; Patel P; Tao L; Neelapu S; Maitra A
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
    Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
    Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
    Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
    Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
    Li J; Yuan S; Norgard RJ; Yan F; Yamazoe T; Blanco A; Stanger BZ
    Cancer Immunol Res; 2020 Mar; 8(3):282-291. PubMed ID: 31871120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
    Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
    Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study.
    Zhang H; Chen J; Bai J; Zhang J; Huang S; Zeng L; Zhou P; Shen Q; Yin T
    Int J Surg; 2024 May; 110(5):2679-2691. PubMed ID: 38489548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
    Cardot-Ruffino V; Bollenrucher N; Delius L; Wang SJ; Brais LK; Remland J; Keheler CE; Sullivan KM; Abrams TA; Biller LH; Enzinger PC; McCleary NJ; Patel AK; Rubinson DA; Schlechter B; Slater S; Yurgelun MB; Cleary JM; Perez K; Dougan M; Ng K; Wolpin BM; Singh H; Dougan SK
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
    Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
    Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
    Bunt SK; Mohr AM; Bailey JM; Grandgenett PM; Hollingsworth MA
    Cancer Immunol Immunother; 2013 Feb; 62(2):225-36. PubMed ID: 22864396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenylboronic acid modified nanoparticles simultaneously target pancreatic cancer and its metastasis and alleviate immunosuppression.
    Lu Z; Long Y; Wang Y; Wang X; Xia C; Li M; Zhang Z; He Q
    Eur J Pharm Biopharm; 2021 Aug; 165():164-173. PubMed ID: 34020022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
    Byrne KT; Vonderheide RH
    Cell Rep; 2016 Jun; 15(12):2719-32. PubMed ID: 27292635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
    Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
    Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
    Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
    Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.